Monocytes from MS patients undergoing IFN-β treatment make substantially less IL-1β than monocytes derived from healthy donors, which implies that anti-IFN autoantibodies may contribute to an increase in inflammatory cytokines produced by monocytes [84]. Here, IL1B is linked to myeloid sarcoma.